Use the hyperlinks, where available to access additional clinical trial information.
A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Eligible participants will be randomly allocated to one of two experimental arms. In Experimental Arm A, participants will receive acalbrutinib plus venetoclax, both administered orally. In Experimental Arm B, participants will receive venetoclax, administered orally, plus obinutuzumab, administered via intravenous infusion.